表紙
市場調査レポート

抗嘔吐薬:世界の産業・市場分析

Antiemetic Drugs: World Industry and Market Analysis 2014-2024

発行 Visiongain Ltd 商品コード 302478
出版日 ページ情報 英文 121 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=136.36円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
抗嘔吐薬:世界の産業・市場分析 Antiemetic Drugs: World Industry and Market Analysis 2014-2024
出版日: 2014年05月19日 ページ情報: 英文 121 Pages
概要

世界の抗嘔吐薬市場は2018年に46億米ドルに達し、2024年まで更に拡大すると予測されています。

当レポートでは、世界の抗嘔吐薬市場について調査し、4つの2次市場(5-HT3拮抗薬・カンナビノイド・ドーパミン拮抗薬・その他)と8つの主要製品(パロノセトロン・オンダンセトロン・グラニセトロン・ドラセトロン・ドロナビノール・ナビロン・メトクロプラミド・ドンペリドン)の生産・マーケティング・販売展望、主要11カ国市場の収益・販売拡大予測、既存企業・新興企業・新規参入企業の展望などを提供しています。

第1章 レポート概要

第2章 嘔吐・抗嘔吐薬:イントロダクション

  • 嘔吐とは?
  • 嘔吐の原因と合併症
  • 嘔吐の診断:総合的アプローチの必要性
  • 嘔吐の治療および薬理学的マネジメントのアプローチ

第3章 世界の抗嘔吐薬市場

  • 世界の抗嘔吐薬市場
  • 世界の抗嘔吐薬市場:収益予測
  • 主要な抗嘔吐薬クラスの市場シェア変化予測

第4章 5-HT3拮抗薬市場

  • 5-HT3拮抗薬市場
  • 5-HT3拮抗薬市場:収益予測
  • 5-HT3拮抗薬市場:主要医薬品別の収益予測
  • 主要な5-HT3拮抗薬の市場シェア変化予測

第5章 カンナビノイド薬市場

  • カンナビノイド薬市場
  • カンナビノイド薬市場:収益予測
  • カンナビノイド薬市場:主要医薬品別の収益予測
  • 主要なカンナビノイド薬の市場シェア変化予測

第6章 ドーパミン拮抗薬市場

  • ドーパミン拮抗薬市場
  • ドーパミン拮抗薬市場:収益予測
  • ドーパミン拮抗薬市場:主要医薬品別の収益予測
  • 主要なドーパミン拮抗薬の市場シェア変化予測

第7章 主要国市場

  • 抗嘔吐薬の主要国市場
  • 世界の抗嘔吐薬市場:地域別の収益予測
  • 米国
  • EU5ヶ国
  • 日本
  • ロシア
  • 中国
  • インド
  • ブラジル

第8章 抗嘔吐薬市場:R&Dパイプライン

  • 新治療薬・分子標的の発見
  • セロトニン標的:5-HT3拮抗薬の臨床成功を拡大
  • カンナビノイド:R&Dパイプライン開発
  • ドーパミン拮抗薬:R&Dパイプライン開発
  • その他、開発中の新薬

第9章 世界の抗嘔吐薬市場:産業動向

  • 世界の抗嘔吐薬市場のSWOT分析
  • 強み
  • 弱み
  • 機会
  • 脅威
  • 世界の抗嘔吐薬市場のSTEP分析

第10章 調査インタビュー

第11章 結論

  • 世界の抗嘔吐薬市場:現況
  • 世界の抗嘔吐薬市場の展望

図表

目次

Treatments for nausea and vomiting - explore business trends, R&D, and revenue forecasts

What's the future of treating nausea and vomiting? For those medicines you get sales predictions, also exploring research and development. Those treatments hold high potential. There you assess results, progress, therapies, and opportunities.

Visiongain's new report forecasts those revenues to 2024 at overall world market, submarket, product, and national level. Discover business potentials - trends, technologies, and new drugs.

Read on to explore anti-nausea and anti-vomiting therapies, seeing their potential revenue.

Forecasts to 2024 and other analyses explain and predict that pharma market

Why miss data you need? Why struggle to find it? Instead our report gives you revenue forecasts to 2024 for those pharmaceuticals. There find results, growth rates, market shares, and discussions.

Also you explore research and development (R&D). That study gives 41 tables, 48 charts, and an interview with a company. There find how you could benefit your authority and save time, staying ahead.

That study lets you assess the future of treating nausea and vomiting - especially in cancer treatment - exploring rising needs and demands. You find where opportunities and money lie. See, from 2014, where best selling prospects exist.

And the following sections show how that new investigation benefits your research, analyses and decisions.

Forecasting of that world market and its main segments

In our report you discover overall world revenue to 2024 for antiemetic medicines, with discussions.

You also find individual revenue predictions to 2024 for four submarkets at world level - drug classes:

  • 5-HT3 antagonists
  • Cannabinoids
  • Dopamine antagonists
  • Other agents (grouped).

There you assess outlooks for expansion in trade, hearing where you could gain. That work investigates therapies, uses, and rising sales. Our study also explores competition.

There you hear what's happening for developers, producers, and sellers of antiemetic agents, understanding challenges, trends, and rising sales.

That work also splits its overall world market into products.

Predictions of leading treatments' sales

How will drugs perform to 2024 at world level? Our study forecasts individual revenues of eight top products:

  • Palonosetron
  • Ondansetron
  • Granisetron
  • Dolasetron
  • Dronabinol
  • Nabilone
  • Metoclopramide
  • Domperidone.

There you find medicines and years with highest predicted sales. You also examine competitors. See, then, what's happening, understanding, challenges, trends, and outlooks.

The new study also gives geographical revenue predictions.

Healthcare in national markets - what outlooks for that business?

In developed and developing countries, many opportunities for developers, producers, and sellers of antiemetic medicines will occur from 2014 to 2024. See where and how.

Our analyses show individual revenue forecasts to 2024 for 11 national markets:

  • United States (US)
  • Japan
  • Germany, France, UK, Italy, and Spain (EU5)
  • Brazil, Russia, India, and China (BRIC nations).

There you find countries with highest revenues, demand, and potential sales growth. Explore progress, needs and opportunities.

Also what events, challenges and advances in technology affect that industry and market? Our work shows you, discussing progress, policies, and R&D.

Market forces and issues - developments, challenges, and events influencing business

The report also explains issues, forces, and events affecting the antiemetic drugs industry and market from 2014, including these:

  • Emesis and its pharmacological management - pathways and targets
  • Future of serotonin (5-HT3) antagonists - existing and new therapies
  • Demand for antiemetics in post-operative settings, inc. cancer and other diseases
  • Drug delivery to improve patient compliance.

And you assess these trends and influences, among others:

  • Improvements in design of clinical trials for those treatments
  • Effects of investments in healthcare, esp. in emerging countries
  • Improvements to therapy, inc. using antihistamines and prolonging drug action
  • Efforts to develop new drugs - R&D harnessing new receptors and mechanisms of action, with emerging technologies.

There you explore political, economic, social, and technological questions, as well as strengths weaknesses, opportunities, and threats. Discover what the future holds. See, too, how R&D helps companies benefit patients and expand that market.

You find, then, what stimulates and restrains firms in that sector, affecting its results.

Antiemetic medicines - opportunities and 2018 market value

Our study predicts that overall world market will reach $4.6bn in 2018, with further expansion to 2024.

There large pharmaceutical corporations and specialty companies can gain. See how.

From 2014 to 2024 that industry holds many opportunities. And you examine its technological and commercial possibilities, staying ahead in knowledge.

Ways Antiemetic Drugs: World Industry and Market Analysis 2014-2024 helps

In these main ways, that investigation helps your work:

  • Revenues to 2024 at world level, for 4 submarkets, and 8 leading products - assess outlooks for production, marketing, and sales
  • Forecasts to 2024 for 11 national markets in the Americas, Europe, and Asia - investigate countries for revenues and sales expansion
  • Prospects for established competitors, rising companies, and new entrants - explore portfolios, results, actions, R&D, and outlooks for success.

Knowledge there found nowhere else, benefiting your searches, analyses, and planning

Our work gives independent analysis. There you receive business intelligence found only in our report, seeing where prospects are most rewarding.

With that investigation you're less likely to fall behind in information or miss opportunity. See there how you can choose to benefit your searches, analyses and decisions, also saving time and helping your influence.

Our new study is for everyone analysing medications for nausea and vomiting. There you find data, trends, opportunities and sales predictions. Please get that report here now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Overview of Report

  • 1.1. Antiemetic Drug Treatments: World Market Review
  • 1.2. Content of Report Chapters
  • 1.3. Research and Analysis Methods

2. Introduction to Emesis and Antiemetic Drugs

  • 2.1. What is Emesis?
    • 2.1.1. The Process of Emesis: The Role of the Vomiting Centre
  • 2.2. Causes and Complications of Vomiting Vary
    • 2.2.1. Most Common Triggers of Vomiting
  • 2.3. Diagnosing Emesis: Multidisciplinary Approach Required
  • 2.4. Treating Emesis and the Approach to Pharmacological Management
    • 2.4.1. Serotonin (5-HT3) Antagonists: Gold Standard Treatment
    • 2.4.2. Cannabinoids: Controversial Choice, But Interest Remains
    • 2.4.3. Dopamine Antagonists: Effective in Post-Operative Setting
    • 2.4.4. Other Therapies

3. The Global Antiemetic Drug Market, 2014-2024

  • 3.1. The Global Antiemetic Drug Market, 2013
    • 3.1.1. Leading Antiemetic Drugs, 2013
  • 3.2. The Global Antiemetic Drug Market: Revenue Forecast, 2014-2024
    • 3.2.1. What Will Drive The Global Antiemetic Drug Market Between 2014 and 2024?
      • 3.2.1.1. Growing Incidence of Cancer and Other Diseases
      • 3.2.1.2. Increased Research Efforts Focused on New Therapies
      • 3.2.1.3. Identifying New Drug Targets Through Technology
      • 3.2.1.4. Launch of Novel Delivery Methods to Encourage Patient Compliance
    • 3.2.2. What Factors are Likely to Restrain the Global Antiemetic Drug Market Between 2014 and 2024?
      • 3.2.2.1. Improvements Needed in Design of Antiemetic Clinical Trials
      • 3.2.2.2. High Cost of Alternative Animal Models
  • 3.3. How Will the Market Shares of Leading Antiemetic Drug Classes Change From 2014-2024?

4. The 5-HT3 Antagonists Drug Market, 2014-2024

  • 4.1. The 5-HT3 Antagonists Drug Market, 2013
  • 4.2. The 5-HT3 Antagonists Drug Market: Revenue Forecast, 2014-2024
    • 4.2.1. The 5-HT3 Antagonists Drug Market: Industry Trends, 2014-2024
  • 4.3. The 5-HT3 Antagonists Drug Market: Revenue Forecasts of Leading Drugs, 2014-2024
    • 4.3.1. Palonosetron (Aloxi®): Revenue Forecast, 2014-2024
    • 4.3.2. Ondansetron (Zofran®): Revenue Forecast, 2014-2024
    • 4.3.3. Granisetron (Sancuso®): Revenue Forecast, 2014-2024
    • 4.3.4. Dolasetron (Anzemet®): Revenue Forecast, 2014-2024
  • 4.4. How Will Market Shares of Leading 5-HT3 Antagonist Drugs Change from 2014-2024?

5. The Cannabinoids Drug Market, 2014-2024

  • 5.1. The Cannabinoids Drug Market, 2013
  • 5.2. The Cannabinoids Drug Market: Revenue Forecast, 2014-2024
    • 5.2.1. The Cannabinoids Drug Market: Industry Trends, 2014-2024
  • 5.3. The Cannabinoids Drug Market: Revenue Forecast by Leading Drugs, 2014-2024
    • 5.3.1. Dronabinol (Marinol®): Revenue Forecast, 2014-2024
    • 5.3.2. Nabilone (Cesamet®): Revenue Forecast, 2014-2024
  • 5.4. How Will the Market Shares of Leading Cannabinoid Drugs Change from 2014-2024?

6. The Dopamine Antagonists Drug Market, 2014-2024

  • 6.1. The Dopamine Antagonists Drug Market, 2013
  • 6.2. The Dopamine Antagonists Drug Market: Revenue Forecast, 2014-2024
    • 6.2.1. The Dopamine Antagonists Drug Market: Industry Trends, 2014-2024
  • 6.3. The Dopamine Antagonists Drug Market: Revenue Forecast by Leading Drugs, 2014-2024
    • 6.3.1. Metoclopramide (Reglan®): Revenue Forecast, 2014-2024
    • 6.3.2. Domperidone (Motilium®): Revenue Forecast, 2014-2024
  • 6.4. How Will Market Shares of Leading Dopamine Antagonist Drugs Change from 2014-2024?

7. Leading National Markets for Antiemetic Drugs, 2014-2024

  • 7.1. Leading National Markets for Antiemetic Drugs, 2013
  • 7.2. The Global Antiemetic Drug Market: Revenue Forecasts by Region, 2014-2024
  • 7.3. The US Antiemetic Drug Market: Revenue Forecast, 2014-2024
    • 7.3.1. Novel Drug Formulation to Increase Compliance
  • 7.4. The Antiemetic Drug Market in Leading EU Countries (EU5), 2013
    • 7.4.1. The Antiemetic Drug Market in the EU5: Revenue Forecasts by Country, 2014-2024
      • 7.4.1.1. The German Antiemetic Drug Market: Revenue Forecast, 2014-2024
      • 7.4.1.2. The French Antiemetic Drug Market: Revenue Forecast, 2014-2024
      • 7.4.1.3. The UK Antiemetic Drug Market: Revenue Forecast, 2014-2024
      • 7.4.1.4. The Italian Antiemetic Drug Market: Revenue Forecast, 2014-2024
      • 7.4.1.5. The Spanish Antiemetic Drug Market: Revenue Forecast, 2014-2024
  • 7.5. The Japanese Antiemetic Drug Market: Revenue Forecast, 2014-2024
  • 7.6. The Russian Antiemetic Drug Market: Revenue Forecast, 2014-2024
  • 7.7. The Chinese Antiemetic Drug Market: Revenue Forecast, 2014-2024
    • 7.7.1. Strong Incentives Prompt Entry of New Companies
    • 7.7.2. Multi-Billion Dollar Investment to Improve Healthcare
  • 7.8. The Indian Antiemetic Drug Market: Revenue Forecast, 2014-2024
    • 7.8.1. Difficulties in Drug Distribution May Restrict Market
  • 7.9. The Brazilian Antiemetic Drug Market: Revenue Forecast, 2014-2024
    • 7.9.1. Restrictions on Foreign Companies May Stifle Market Growth

8. The Antiemetic Drug Market: R&D Pipeline, 2014

  • 8.1. Discovering New Treatments and Molecular Targets
  • 8.2. Targeting Serotonin: Expanding on the Clinical Success of 5-HT3 Antagonists
    • 8.2.1. Sustol (APF-530; Heron Therapeutics): Enhanced Duration of Action
    • 8.2.2. RHB-102 (RedHill Biopharma): Consistent Bioequivalency with Marketed Therapy
    • 8.2.3. ETI-385 (Epiomed): Aiming to Target Multiple Emesis Pathways
  • 8.3. Cannabinoids: R&D Pipeline Developments
    • 8.3.1. Dronabinol Oral Solution (INSYS Therapeutics): Improved Bioavailability
  • 8.4. Dopamine Antagonists: R&D Pipeline Developments
    • 8.4.1. APD421 (Acacia Pharma): New Indication for Drug?
    • 8.4.2. APD403 (Acacia Pharma): Potential Market Leader?
  • 8.5. Other Novel Drugs Under Development
    • 8.5.1. NK1 Receptor Antagonists
      • 8.5.1.1. Netupitant-Palonosetron (Helsinn Healthcare): Dual Drug Combination
      • 8.5.1.2. Rolapitant (OPKO Health/TESARO): Therapy Offering Prolonged, 5-day Effect
      • 8.5.1.3. Vestipitant (GW597599; GSK): Applications in Numerous Therapeutic Areas?
    • 8.5.2. Antihistamines
      • 8.5.2.1. CL-108 (Charleston Laboratories): Targeting Emesis and Pain
    • 8.5.3. Non-Pharmacological Therapies
      • 8.5.3.1. Zindol (Aphios Corporation): Ginger-based Therapy

9. World Antiemetic Drug Market: Industry Trends, 2014-2024

  • 9.1. SWOT Analysis of the Global Antiemetic Drug Market, 2014-2024
  • 9.2. Strengths
    • 9.2.1. The Drive to Discover a Universal Therapy
    • 9.2.2. Varied Market Landscape Containing Big and Small Players
  • 9.3. Weaknesses
    • 9.3.1. Antiemetic Trials Need Overhaul
  • 9.4. Opportunities
    • 9.4.1. Global Increase in Cancer Prevalence
    • 9.4.2. Secondary Indications Encourage Companies to Enter Market
  • 9.5. Threats
    • 9.5.1. Concerns of Cardiac Side Effects of Market-Leading Drugs
    • 9.5.2. Wearable Devices: Stimulating Neural Emesis Pathways
  • 9.6. STEP Analysis of the Global Antiemetic Drug Market, 2014-2024
    • 9.6.1. Social Factors
    • 9.6.2. Technological Advances
    • 9.6.3. Economic Pressures
    • 9.6.4. Political Issues

10. Research Interview

  • 10.1. Interview with a Respondent from a Company Marketing Antiemetic Therapies
    • 10.1.1. The Current Antiemetic Drug Market and Demand in the Asia-Pacific Region
    • 10.1.2. Market Competition and Common Diseases Triggering Emesis
    • 10.1.3. Current and Future Directions for Antiemetic Therapy

11. Conclusions

  • 11.1. The Global Antiemetic Drug Market - Current Status
  • 11.2. Outlook for the Global Antiemetic Drugs Market, 2014-2024
    • 11.2.1. 5-HT3 Antagonists Will Continue to Dominate the Market
    • 11.2.2. Regional Outlook for the Antiemetic Drugs Market, 2014-2024

List of Tables

  • Table 1.1: Common Abbreviations Used in this Report
  • Table 2.1: Commonly Prescribed Antiemetic Medications, 2014
  • Table 3.1: The Global Antiemetic Drug Market: Revenue ($m) and Market Share (%) by Drug Class, 2013
  • Table 3.2: Leading Antiemetic Drugs: Revenue ($m) and Market Share (%) by Drug, 2013
  • Table 3.3: The Global Antiemetic Drug Market: Revenue Forecasts ($m, AGR %, CAGR %) by Drug Class, 2014-2024
  • Table 3.4: The Global Antiemetic Market: Market Shares (%) by Drug Class, 2014-2024
  • Table 4.1: The 5-HT3 Antagonists Drug Market: Revenue ($m) and Market Share (%) by Leading Drug, 2013
  • Table 4.2: The 5-HT3 Antagonists Drug Market: Revenue Forecasts ($m, AGR %, CAGR %) by Leading Drug, 2014-2024
  • Table 4.3: Palonosetron: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
  • Table 4.4: Ondansetron: Revenue Forecast ($m, AGR, CAGR %), 2014-2024
  • Table 4.5: Granisetron: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
  • Table 4.6: Dolasetron: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
  • Table 4.7: The 5-HT3 Antagonists Drug Market: Market Shares (%) by Drug, 2014-2024
  • Table 5.1: The Cannabinoids Drug Market: Revenue ($m) and Market Shares (%) by Leading Drug, 2013
  • Table 5.2: The Cannabinoids Drug Market: Revenue Forecasts ($m, AGR %, CAGR %) by Leading Drug, 2014-2024
  • Table 5.3: Dronabinol: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
  • Table 5.4: Nabilone: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
  • Table 5.5: The Cannabinoids Drug Market: Market Share (%) by Drug, 2014-2024
  • Table 6.1: The Dopamine Antagonists Drug Market: Revenues ($m) and Market Shares (%) by Leading Drug, 2013
  • Table 6.2: The Dopamine Antagonists Drug Market: Revenue Forecasts ($m, AGR %, CAGR %) by Leading Drug, 2014-2024
  • Table 6.3: Metoclopramide: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
  • Table 6.4: Domperidone: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
  • Table 6.5: The Dopamine Antagonists: Market Shares (%) by Drug, 2014-2024
  • Table 7.1: The Global Antiemetic Drug Market: Revenues ($m) and Market Shares (%) by Region, 2013
  • Table 7.2: The Global Antiemetic Drug Market: Revenue Forecasts ($m, AGR %, CAGR %) by Region, 2014-2024
  • Table 7.3: The US Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
  • Table 7.4: The EU5 Antiemetic Drug Market: Revenue ($m), EU5 Market Share (%) and Global Market Share (%) by Country, 2013
  • Table 7.5: The EU5 Antiemetic Drug Market: Revenue Forecasts ($m, AGR %, CAGR %) for Leading Countries, 2014-2024
  • Table 7.6: The German Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
  • Table 7.7: The French Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
  • Table 7.8: The UK Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
  • Table 7.9: The Italian Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
  • Table 7.10: The Spanish Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
  • Table 7.11: The Japanese Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
  • Table 7.12: The Russian Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
  • Table 7.13: The Chinese Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
  • Table 7.14: The Indian Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
  • Table 7.15: The Brazilian Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024
  • Table 9.1: SWOT Analysis of the World Antiemetic Drugs Market, 2014-2024
  • Table 11.1: The World Antiemetic Drugs Market: Revenue Forecasts ($m, AGR %, CAGR %) and Market Shares (%) by Drug Class, 2013, 2018 and 2024
  • Table 11.2: The World Antiemetic Drugs Market: Revenue Forecasts ($m, AGR %, CAGR %) and Market Shares (%) by Region, 2013, 2018 and 2024

List of Figures

  • Figure 3.1: The Global Antiemetic Drug Market: Revenue ($m) by Drug Class, 2013
  • Figure 3.2: The Global Antiemetic Drug Market: Market Shares (%) by Drug Class, 2013
  • Figure 3.3: Leading Antiemetic Drugs: Market Share (%) by Drug, 2013
  • Figure 3.4: The Global Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024
  • Figure 3.5: The Global Antiemetic Drug Market: Drivers and Restraints, 2014-2024
  • Figure 3.6: The Global Antiemetic Drug Market: Market Shares (%) by Drug Class, 2018
  • Figure 3.7: The Global Antiemetic Drug Market: Revenue Shares (%) by Drug Class, 2024
  • Figure 4.1: The 5-HT3 Antagonists Drug Market: Revenue ($m) by Leading Drug, 2013
  • Figure 4.2: The 5-HT3 Antagonists Drug Market: Market Shares (%) by Leading Drug, 2013
  • Figure 4.3: The 5-HT3 Antagonists Drug Market: Revenue Forecast ($m), 2014-2024
  • Figure 4.4: Palonosetron: Revenue Forecast ($m), 2014-2024
  • Figure 4.5: Ondansetron: Revenue Forecast ($m), 2014-2024
  • Figure 4.6: Granisetron: Revenue Forecast ($m), 2014-2024
  • Figure 4.7: Dolasetron: Revenue Forecast ($m), 2014-2024
  • Figure 4.8: The 5-HT3 Antagonists Drug Market: Market Shares (%) by Drug, 2018
  • Figure 4.9: The 5-HT3 Antagonists Drug Market: Market Shares (%) by Drug, 2024
  • Figure 5.1: The Cannabinoids Drug Market: Revenue ($m) by Leading Drug, 2013
  • Figure 5.2: The Cannabinoids Drug Market: Market Shares (%) by Leading Drug, 2013
  • Figure 5.3: The Cannabinoids Drug Market: Revenue Forecast ($m), 2014-2024
  • Figure 5.4: Dronabinol: Revenue Forecast ($m), 2014-2024
  • Figure 5.5: Nabilone: Revenue Forecast ($m), 2014-2024
  • Figure 5.6: The Cannabinoids Drug Market: Market Shares (%) by Drug, 2018
  • Figure 5.7: The Cannabinoids Drug Market: Market Shares (%) by Drug, 2024
  • Figure 6.1: The Dopamine Antagonists Drug Market: Revenues ($m) by Leading Drug, 2013
  • Figure 6.2: The Dopamine Antagonists Drug Market: Market Shares (%) by Leading Drug, 2013
  • Figure 6.3: The Dopamine Antagonists Drug Market: Revenue Forecast ($m), 2014-2024
  • Figure 6.4: Metoclopramide: Revenue Forecast ($m), 2014-2024
  • Figure 6.5: Domperidone: Revenue Forecast ($m), 2014-2024
  • Figure 6.6: The Dopamine Antagonists Drug Market: Market Shares (%) by Drug, 2018
  • Figure 6.7: The Dopamine Antagonists Drug Market: Market Shares (%) by Drug, 2024
  • Figure 7.1: The Global Antiemetic Drug Market: Revenue ($m) by Region, 2013
  • Figure 7.2: The Global Antiemetic Drug Market: Market Shares (%) by Region, 2013
  • Figure 7.3: The US Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024
  • Figure 7.4: The EU5 Antiemetic Drug Market: Revenue ($m) by Country, 2013
  • Figure 7.5: The EU5 Antiemetic Drug Market: Market Shares (%) by Country, 2013
  • Figure 7.6: The EU5 Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024
  • Figure 7.7: The German Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024
  • Figure 7.8: The French Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024
  • Figure 7.9: The UK Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024
  • Figure 7.10: The Italian Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024
  • Figure 7.11: The Spanish Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024
  • Figure 7.12: The Japanese Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024
  • Figure 7.13: The Russian Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024
  • Figure 7.14: The Chinese Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024
  • Figure 7.15: The Indian Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024
  • Figure 7.16: The Brazilian Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024
  • Figure 11.1: The Global Antiemetic Drug Market: Revenue Forecasts ($m) by Drug Class, 2013, 2018 and 2024
  • Figure 11.2: The Global Antiemetic Drug Market: Revenue Forecasts ($m) by Region, 2013, 2018 and 2024

Companies Listed

  • Acacia Pharma
  • American Society of Clinical Oncology
  • Aphios Corporation
  • Aptalis Pharma
  • Astra Zeneca
  • Charleston Laboratories
  • Eisai
  • Epiomed Therapeutics
  • European Medicines Agency (EMA)
  • Food and Drug Administration (FDA)
  • GlaxoSmithKline (GSK)
  • Helsinn Healthcare
  • Heron Therapeutics
  • INSYS Therapeutics
  • Italian Group for Clinical Research (G.O.I.R.C)
  • MacMillan Cancer Care
  • Merck and Co.
  • MHRA (Medicines and Healthcare Products Regulatory Agency)
  • Multinational Association of Supportive Care in Cancer
  • Mundipharma
  • N.N. Petrov Institute of Oncology
  • National Government Services (NGS)
  • Neurowave Medical Technologies
  • OPKO Health
  • ProStrakan
  • RedHill Biopharma
  • Roche
  • Schering Plough Corporation
  • Schwarz Pharma
  • SCOLR Pharma
  • TESARO
  • Vifor Pharma
Back to Top